The role of pemetrexed in recurrent epithelial ovarian cancer

A scoping review

Michael Roche, Laura Parisi, Linda Li, Amy Knehans, Rebecca Phaeton, Joshua Kesterson

Research output: Contribution to journalReview article

Abstract

Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (Alimta T M ) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current lit¬ erature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.

Original languageEnglish (US)
Pages (from-to)8-13
Number of pages6
JournalOncology Reviews
Volume12
Issue number1
DOIs
StatePublished - Jan 30 2018

Fingerprint

Pemetrexed
Folic Acid Antagonists
Ovarian Neoplasms
Recurrence
Mortality
Ovarian epithelial cancer
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{aef15a6a200d4d62aec7281d1053f47a,
title = "The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review",
abstract = "Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (Alimta T M ) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current lit¬ erature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.",
author = "Michael Roche and Laura Parisi and Linda Li and Amy Knehans and Rebecca Phaeton and Joshua Kesterson",
year = "2018",
month = "1",
day = "30",
doi = "10.4081/oncol.2018.346",
language = "English (US)",
volume = "12",
pages = "8--13",
journal = "Oncology Reviews",
issn = "1970-5557",
publisher = "PagePress",
number = "1",

}

The role of pemetrexed in recurrent epithelial ovarian cancer : A scoping review. / Roche, Michael; Parisi, Laura; Li, Linda; Knehans, Amy; Phaeton, Rebecca; Kesterson, Joshua.

In: Oncology Reviews, Vol. 12, No. 1, 30.01.2018, p. 8-13.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The role of pemetrexed in recurrent epithelial ovarian cancer

T2 - A scoping review

AU - Roche, Michael

AU - Parisi, Laura

AU - Li, Linda

AU - Knehans, Amy

AU - Phaeton, Rebecca

AU - Kesterson, Joshua

PY - 2018/1/30

Y1 - 2018/1/30

N2 - Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (Alimta T M ) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current lit¬ erature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.

AB - Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (Alimta T M ) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current lit¬ erature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=85049181480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049181480&partnerID=8YFLogxK

U2 - 10.4081/oncol.2018.346

DO - 10.4081/oncol.2018.346

M3 - Review article

VL - 12

SP - 8

EP - 13

JO - Oncology Reviews

JF - Oncology Reviews

SN - 1970-5557

IS - 1

ER -